Blog

Sodium valproate (VPA) is usually regarded as the best available antiseizure medication (ASM) in generalized genetic epilepsies (GGEs), such as juvenile myoclonic epilepsy (JME), juvenile absence epilepsy (JAE), epilepsy with generalized tonic‒clonic seizures alone (GTCA), and epilepsy with eyelid myoclonia (EEM), with the potential to control all seizure types present in these epilepsy syndromes [1,2,3]. Compared with currently used ASMs, VPA showed superiority in controlling myoclonic (MS) and generalized tonic‒clonic seizures (GTCS) and a reasonable effect in absence seizures (AS) [2,3,4].